Skip to main content

Table 4 Comparative evaluation of FDA-EUA versus COVAM serology by symptom characteristics

From: Infection prevention strategies are highly protective in COVID-19 units while main risks to healthcare professionals come from coworkers and the community

  Symptom characteristics by serology assay Percent seropositive within each symptom category
FDA-EUA assay or microarray N (%) of
FDA-EUA serology with characteristic
N (%) of COVAM serology with characteristic p value N (%) of characteristic with positive FDA-EUA serology N (%) of characteristic with positive COVAM serology
Seropositive—total 87 53 78  < 0.01 60.9% 89.7%
Reported to occupational health 67 (77.0) 46 (86.8) 63 (80.8) NS 68.7% 94.0%
Any symptom reported 62 (71.3) 42 (79.2) 58 (74.4) NS 67.7% 93.5%
No symptom reported 25 (28.7) 11 (20.8) 20 (25.6) NS 44.0% 80.0%
Symptom type
 Non febrile illness 19 (21.8) 8 (15.1) 16 (20.5) NS 42.1% 84.2%
 Fever 43 (49.4) 34 (64.2) 42 (53.8) NS 79.1% 97.7%
 Fatigue 49 (56.3) 35 (66.0) 46 (59.0) NS 71.4% 93.9%
 Chills 46 (52.9) 34 (64.2) 43 (55.1) NS 73.9% 93.5%
 Myalgia 47 (54.0) 33 (62.3) 45 (57.7) NS 70.2% 95.7%
 Congestion 42 (48.3) 25 (47.2) 39 (50.0) NS 59.5% 92.9%
 Cough 37 (42.5) 28 (52.8) 34 (43.6) NS 75.7% 91.9%
 Loss of smell 30 (34.5) 28 (52.8) 30 (38.5) NS 93.3% 100.0%
 Shortness of breath 21 (24.1) 16 (30.2) 19 (24.4) NS 76.2% 96.3%
Days between symptoms and serology sample collection     NS   
 < 14 days 4 (4.6) 3 (5.7) 4 (5.1)   75.0% 100.0%
 15–29 days 10 (11.5) 8 (15.1) 9 (11.5)   80.0% 90.0%
 30–44 days 7 (8.0) 7 (13.2) 7 (9.0)   100.0% 100.0%
 45–59 days 23 (26.4) 19 (35.8) 23 (29.5)   82.6% 100.0%
 60–74 days 2 (2.3) 1 (1.9) 2 (2.6)   50.0% 100.0%
 ≥ 75 days 15 (17.2) 4 (7.5) 12 (15.4)   26.7% 80.0%
  1. FDA-EUA, Food and drug administration emergency use authorization; COVAM, coronavirus antigen microarray
  2. ap value = chi square comparing FDA-EUA with COVAM serology